The Food and Drug Administration granted ARCA biopharma Inc.'s (Nasdaq: ABIO) chronic heart failure treatment Gencaro fast-track status. The stock price nearly doubled by rocketing $2.07 to close at $4.32.
ARCA's Gencaro Granted Fast-Track Status
November 23, 2009 at 16:07 PM EST
